Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:22 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
NCT03836157 · University of Oklahoma · PHASE2 · withdrawn · last registry update 2019-06-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study was not initiated.” | – | Registry record, University of Oklahoma |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FOLR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-06-09Results posted on the registry: ImmunoGen, Inc., Mirvetuximab soravtansine + Paclitaxel (NCT02631876)
- 2020-03-05Phase 3 first posted: ImmunoGen, Inc., Mirvetuximab Soravtansine (NCT04296890)
- 2019-12-24Phase 3 first posted: AbbVie, Mirvetuximab Soravtansine + Paclitaxel (NCT04209855)
- 2018-07-05Also stopped (withdrawn): Duke University, Mirvetuximab Soravtansine (IMGN853) (NCT03045393)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision